To investigate how and to what extent platycodin saponin (PS) from Platycodi Radix exerts a favorable influence on obesity and hyperlipidemia. DESIGN: Sprague-Dawley rats were fed with a high fat (HF) diet for 4 weeks and then the animals were treated with 35 or 70 mg/kg of PS for another 4 weeks. Changes in body weight and daily calorie intake were measured regularly during the experimental period and the degree of linear correlation for the above two variables was further analyzed. The in vitro lipase inhibition of each PS compound and the in vivo fecal lipid excretion were examined in hope of revealing their relationship. The concentrations of hepatic triglyceride and cholesterol in serum. RESULTS: The body weight reduction (1374% vs HF control, Po0.05) by PS administration was highly correlated to the food intake restriction (Pearson's linear coefficient r ¼ 0.752, Po0.005). The in vitro inhibition of lipase by each isolated compound and mixture of PS were virtually identical. Consequently, the fecal TG excretion was increased by 2.1-3.2 folds depending on the dose of PS. The serum TG and LDL-cholesterol concentrations were decreased without noticeable changes in HDLcholesterol levels. Concomitantly, the contents of the hepatic TG, cholesterol, and the liver surface fat pads were decreased in ubiquity, but no noticeable biochemical abnormalities or histological tissue damages were observed. CONCLUSIONS: The administration of PS produced profound effects on the control of obesity and lipid metabolism, which resulted in LDL-cholesterol reduction. PS also caused a remarkable reduction in calorie intake, which was highly correlated to the body weight loss. These results suggest that PS has a greater role in antiobesity, hypolipidemia, and liver protection than previously thought. Hence, PS could be a potential therapeutic alternative in the treatment of obesity and hyperlipidemia.
Introduction
The prevalence of obesity and its complications, such as coronary heart disease, diabetes, hyperlipidaemia, hypertension, are continuously increasing. Obesity results from the disequilibrium between energy intake and expenditure. A decrease in calorie intake, especially from fat consumption, is one of the essential steps in the treatment of obesity. A lipase inhibitor which reduces fat digestion and thus absorption, is one of widely accepted approaches in decreasing calorie intake. [1] [2] [3] Simple inhibition of lipid digestion and absorption is a prerequisite, but it is not sufficient for a successful long-term control of obesity. 4 Therefore, a coordinated measure to either reduce the food intake efficiency or promote energy expenditure is desirable to achieve a long-term efficacy. Hence, an alternative approach that can reduce the food intake with minimal side effects emerged as another cautiously accepted choice in obesity control. 5, 6 Platycodi Radix (Chinese Jiegeng, Japanese Kikyo, Korean Doraji) is the root of Platycodon grandiflorum A. De (Campanulaceae). 7, 8 It is edible and widely used in traditional
Oriental medicines as an expectorant for pulmonary diseases and a remedy for respiratory disorders. 1 Platycodin saponins (PS) are the primary constituents of Platycodi Radix, 7 responsible for a diversity of effects including antiinflammation, antiallergy, antitumor, augmentation of immune response, and stimulating the apoptosis in skin cells. [8] [9] [10] [11] In the last decade, PS has generated a renewed interest due to its pharmacological potentials for healing the diseases of adulthood such as hyperlipidemia, hypertension, diabetes, and obesity. 1, 2 However, the evidence for the use of PS in obesity and hyperlipidemia treatment is few and sometimes discrepant.
Han et al 1, 2 reported that PS shows antiobese and hypolipidemic effects in part by inhibiting pancreatic lipase; 2 however, no further evidence has been given. In our study, we examined the properties of PS and its derivatives in inhibiting lipase and its efficacy in body weight reduction when administered to high fat (HF) dietinduced obese rats. The animal experiment showed that the body weight reduction was highly linked with the calorie intake restriction, which is obviously inconsistent with the previous reports. 1, 2 We also observed that a cholesterollowering effect was mainly attributed by the reduction of LDL-cholesterol. A beneficial alteration in the hepatic tissues and fecal excretion was also noted.
Methods
Preparation of the mixture, compounds, and derivatives of PS Raw samples of Platycodi Radix were purchased at the local market in Seoul, Korea. The dried samples were extracted twice with methanol by refluxing at 801C for 2 h. The methanol extract (700 g) was suspended in water and partitioned sequentially with n-hexane, chloroform, ethyl acetate, and n-butanol. The water-saturated n-butanol fraction was evaporated to dryness in a vacuum. The recovered crude saponins (80 g) were loaded onto Diaion HP-20 MCI gel (Mitsubishi Chemicals, Japan), and the sugar residues were removed with 40% CH 3 OH. The fractions were then eluted with 60-80% CH 3 OH, collected, and dried to obtain the PS. Some of the PS (100 g) was subjected to repeated silica gel (Merck, Germany) chromatography with open columns. The final purification step was achieved by ZORBAX SB-Aq ODS 18 column (Agilent, Palo Alto, CA, USA) equipped with HPLC (Hitachi, Japan) using an ELSD detector (Sedex 75, Sedere, France). The eluent A (water) and B (acetonitrile) were used according to the following ratios: 0 min: 10% B; 6 min: 15% B; 50 min: 25% B; 70 min: 70% B; 75 min: 10% B. The flow rate was fixed at 1 ml/min. These processes resulted in five pure compounds. 7, 8 They were characterized on the basis of retention times of HPLC, ESI-MS, 1 H-NMR and 13 C-NMR spectra with reference to some authentic samples. They were assigned as 2 00 -O-acetyl polygalacin D (Acetyl PG), platycodin A (PA), polygalacin D (PG), platycodin D (PD), and platycodin D 3 (PD 3 ) , respectively.
The ester-type glycoside is susceptible to acidic or basic hydrolysis. PD (70 mg), one of the major compounds of PS, was dissolved in 5% aqueous KOH (30 ml) and refluxed at 901C for 8 h. The reaction mixture was acidified (pH 3) with diluted HCl and extracted with n-butanol. The organic layer was washed with water, dried in a vacuum, and then subjected to silica gel chromatography to obtain 30 mg of the purified prosapgenin (PRS) D (prs-D, whereby the C-28 glycoside was hydrolyzed and the free carboxyl group exposed). The acqueous layer was precipitated with cold ethanol and the pellet were resuspended in water and filtered with Sephadex LH-20 to obtain the oligosaccharide.
To prepare a prs-D methyl ester (prs-DME), PD (100 mg) was added to 1 M anhydrous potassium methoxide (15 ml) under the conditions of 601C and N 2 atmosphere for 1 h to allow the transesterification reaction. The reaction mixture was neutralized with 0.5 N HCl to precipitate the product. The pellet was subjected to silica chromatography to obtain white compound (20 mg) . The compounds of prs-D and prs-DME were identified on the basis of ESI-MS (Table 3) , 1 H-NMR and 13 C-NMR spectra referring to the results of Hiroashi et al.
7,8
Preparation of the HF diet The HF diet was prepared by mixing the ingredients as listed in Oral administration of PS to obesity-prone rats Male Sprague-Dawley (6 weeks old) rats were obtained from the Animal Center of Seoul National University. The animals were housed at a controlled temperature (21-231C) and ambient humidity (50-60%) with a 12-12 h light-dark cycle. The animals were provided with unrestricted access to the HF-free diet chow and water for at least 1 week prior to any experiments. Platycodin saponins reduce the obesity via lipase inhibition and calorie restriction HL Zhao et al
The obesity-prone rats were selected according to the method of Levin et al. 12 Briefly, the rats were randomly divided into two groups, one group (n ¼ 30) was served the HF diet and the other group (n ¼ 8) was served the HF-free diet. After 4 weeks, the animals fed with HF diet were classified according to the body weight as obesity-prone or as obesity-resistant rats.
The obesity-prone rats were divided into three groups of six animals each. For the two test groups, 35 and 70 mg of PS for per kg of animal weight were orally administered with a needle gavage once a day. To the negative control, the same volume of 0.9% saline was served instead of PS. All of the above three groups were provided with the HF diet throughout the animal test. The normal group (n ¼ 6) served with the HF-free diet was kept throughout the test, for which 0.9% saline was served instead of PS.
The oral administration of PS lasted for 4 weeks and the body weight was measured twice a week. The food intake in each group was also evaluated by monitoring all the food consumption in each cage for 2 consecutive days. The values were converted to calorie intake (kJ/day/rat) and expressed as a percent of HF control.
All of the animal procedures were carried out in accordance with the 'Policy and Regulation for the Care and Use of Laboratory Animals' at Seoul National University.
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Preparation of the serum, hepatic, and fecal specimens The blood was taken by peri-orbital sampling (about 0.5 ml) after 14 h fasting on the last day of the test. The blood specimens were centrifuged at 2000 Â g for 10 min to obtain the serum; the serum was kept at À811C until analysis. After collecting blood, the rats were immediately killed under ether anesthesia; the livers and kidneys were excised, rinsed, weighed and stored at À811C for biochemical assays. Some parts of the livers and kidneys were immersed in the 10% formaldehyde solution and subjected to Masson' Trichrome Staining Test for histological inspection in Korea Green Cross Corp. (Seoul, Korea).
The adipose tissue covering the liver surface was carefully separated and weighed. The livers were next homogenized and extracted with 2:1 (v:v) of chloroform: methanol, 14 the lower layer was dried and resolved in iso-propanol to determine the concentrations of TG and TC (total cholesterol) with the commercial kits (Eiken Chemicals, Japan). The fecal outputs were collected 48 h in advance of the end of the animal test. The collected fecal specimens were freezedried and weighed. The total lipid was extracted with ether for 15 h in a Soxhlet lipid extractor. The extracts were evaporated and resuspended in iso-propanol. TG was then assessed with the commercial kits (Eiken Chemicals, Japan).
Biochemical analysis
The activities of serum ALT (alanine aminotransferase) and AST (aspartate aminotransferase) as well as the concentrations of TG and TC were determined utilizing the commercial kits (Eiken Chemicals, Japan). Each assay is a colorimetric assay with detection of a highly colored end product at 490-520 nm using a microplate reader (Molecular Devices, Sunnyvale, CA, USA). The absorbance of each end product is proportional to the enzyme activity.
The level of HDL-cholesterol (HDL-C) was directly assayed using a diagnostic reagent (Kyowamedex Co., Japan) with a Hitachi-747 autoanalyzer (Tokyo, Japan). The LDL-cholesterol (LDL-C) was estimated according to the following formula. 15 
LDL-C ¼ TC À HDL-C À TG=5
Lipase assay was performed with a Sigma diagnostic kit based on the method of Imamura et al 16 with a slight modification. 17 The IC 50 was established from a series of mean values of triplicate measurements. One unit of lipase activity was defined as the liberation of 1 mmol of free fatty acid per minute under the assay conditions.
Data analysis
Values of animal body weights and fecal outputs were reported as the mean7standard error of mean (s.e.m) of six animals. The other analytical results were also reported as the mean7standard deviation (s.d.) of 5-6 specimens. Differences in mean values between groups were analyzed by a one-way analysis of variance (ANOVA) followed by Duncan's multiple range t test. A P-value of less than 0.05 was considered statistically significant. Linear correlation was estimated with Pearson's Correlation Coefficient at the freedom degree of 13.
Results

Isolation of PD and PRS
The isolated compounds were characterized by spectroscopy and their purity was examined by HPLC (Figures 1 and 2 ).
Body weight and daily calorie intake Following 4 weeks of HF diet, the rats that gained the most body weight were chosen for our experiment (28975.7 g, higher than 27576.6 g of the HF-free diet rats, Po0.05).
The remaining rats were considered as obesity-resistant (229.4710.8 g) and withdrawn from the experiments.
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After 4 weeks of oral administration with 35 or 70 mg/kg of PS, the test animals exhibited a significant reduction in the body weight compared to the HF controls (Po0.05). Some degree of weight reduction was observed within the first 2 weeks (Figure 3 ). Subsequently, a slight rebound of body weight was noted. However, the treatment group maintained a 1374% lower body weight than the HF control group throughout the experiments.
Similarly, a decrease in the daily caloric intake was noted in the first 2 weeks (Table 2 ). PS treatment with the dose of
mg/kg resulted in a significant and dose-dependant decrease in daily calorie intake. In the first week, a decrease in caloric intake in the treatment group of 67% (Po0.05) and 42.2% (Po0.01) compared to the HF control was noted, respectively. In the second week, a 57% (Po0.05) and 75% (Po0.05) reduction in caloric intake compared to the control group was noted, respectively. After then, the calorie intake steadily regressed. However, in the 70 mg/kg PS-treated group, the calorie intake still remained about 20% lower than HF control.
Additionally, the variables reflecting the body weight change and calorie intake were collected from the repeated animal tests. These experiments were performed at different times, doses, and testing periods, but all animal subjects were treated with the same amount of the oral administration of PS. To aid in comparing the results among the different experiments, only those obtained at the first week of the test were used in the statistical analysis. The analysis results revealed that the body weight reduction and calorie intake restriction were highly correlated in the first week of PS administration (Pearson's r ¼ 0.752, Po0.005, Figure 4 ). The dose variation was not taken into consideration in Figure 4 .
Lipase inhibition and fecal lipid excretion
In vitro pancreatic lipase inhibitions by five of the purified PS compounds were listed in Platycodin saponins reduce the obesity via lipase inhibition and calorie restriction HL Zhao et al compounds (Acetyl PG, PA, PG, PD, PD 3 ) possessed similar degrees of inhibition potency, and were similar to that presented by PS mixtures (data not shown). Table 3 also demonstrates that Prs-D, a prosapogenin of PD, exhibited 30% increase in potency of lipase inhibition compared to that of the natural counterpart PD.
Subsequently, the fecal TG outputs in the animal test increased by 2.1 (Po0.05) and 3.2 (Po0.01) folds in a dosedependant manner in 35 and 70 mg/kg of PS-treated animals, respectively ( Figure 5 ).
Biochemical analysis for the serum and hepatic parameters As indicated in Table 4 , PS treatment with 35 or 70 mg/kg doses generated a 28 and 24% decrease in the serum TG and a 41 and 52% decrease in LDL-C, respectively. The total cholesterol (TC) and HDL-C in most of the PS-treated animals were not significantly altered. The ratios of HDL-C/LDL-C recorded a 2.1-2.3-fold rise, while the ratios of TC/HDL-C were not remarkably changed.
Under the same PS administration (Table 5) , the hepatic TG and TC recorded a 39-67 and 49-64% decrease, respectively. The HF diet had induced massive adipose pads to grow on the liver surface, and these fat accumulations had completely disappeared in the 35 mg/kg PS-treated livers; in the 70 mg/kg PS-treated livers, both areas and weights of the fat pads had remarkably diminished.
On the other hand, the serum ALT and AST were almost unaffected by PS administration and no remarkable indications associated with the histological damages in Masson's Trichrome Staining Test of liver and kidney were observed (data not shown).
Discussion
Chemically, PS is a series of triterpenoid bidesmosides (Figure 1 ), composed of a triterpenoidal aglycone moiety linked to two glycosyl side chains. The aglycone moiety linked only with a 3-O-glycosyl chain is PRS. PD is a major component of PS. It can be transformed to prosapogenin D (prs-D) with a mild base-catalyzed hydrolysis, or transformed to prs-DME, a methyl ester of prs-D, in the presence of anhydrous potassium methoxide (Table 3) . 7, 8 In our in vitro study, both the individual compounds and mixture of PS were similar in their inhibition to pancreatic lipase. It seems to indicate that antiobese and antihyperlipi- Platycodin saponins reduce the obesity via lipase inhibition and calorie restriction HL Zhao et al demic effects of PS is not due to a certain particular active component, but each component or mixture of PS can be used alternatively as lipase inhibitor.
Prs-D, free of C-28 sugar residues, showed a 30% increase potency in lipase inhibition, while C-28 sugar residues alone, after separation from PS, showed no lipase inhibition. Since both PS and prs-D are structurally common in PRS moiety, it is likely that the lipase inhibition of PS is mainly determined by the PRS moiety, not by the C-28 sugar residues.
Different C-28 residues of PS derivatives, although not crucial, can slightly adjust the lipase inhibition potency. Compared to natural PD, prs-D have an enhanced lipase inhibition, while prs-DME have slightly reduced lipase inhibition (IC 50 increased, Table 3 ). Hence, C-28 residues act as a minor modulator in PS or PRS for the lipase inhibition.
Owing to the abundance of esterases in the small intestine, the PS may exist in the form of free 28-carboxyl PRS in vivo, such as prs-D of PD. Thus, PS inhibiting lipase might be more potent in vivo than what we have estimated in vitro.
Considering the poor absorption of saponins in the small intestinal tract, nonsystemic action would be essential to illustrate the antiobesity effect of PS. We have proved that PD or PS inhibits the pancreatic lipase in a competitive manner, 17 which means a specific binding of PS to lipase/ colipase. Additionally, it is also possible for PS to nonspecifically bind with cholesterol to form a larger micelle-like complex just as many of typical saponins do. [18] [19] [20] [21] [22] Theoretically, specific binding to lipase or/and nonspecific binding to cholesterol would both promote the excretion of lipid staff with the stools. Not surprisingly, the fecal outputs in PS treated animals were increased by 2.1-3.2-fold in a dose-dependant manner ( Figure 5 ), confirming that PS makes more lipid materials, especially fecal TG, to be excreted without being digested. The consequences of PS as lipase inhibitor were similar to another well-known lipase inhibitor, Orlistat, but much weaker than Orlistat in potency. 18, 23, 24 Han et al 1 have reported that the calorie intake was not affected by the crude PS when 2-5% of PS was served by mixing with chow. However, our observations based on 15 batches of animal tests (Table 2, Figure 4 ) revealed that the food intake was distinctly reduced in a dose-dependent manner at PS treatment and a high degree of linear correlation (Pearson's linear coefficient r ¼ 0.752, Po0.005) between the food intake restriction and the body weight loss was established, particularly in the initial stage of PS administration. The crude PS has been reported to lower the gastric secretion. 25 Treatment of crude PS with a dose of 50 mg/kg (p.o.) reduced the volume of gastric juice, acidic output by about 50%; and in the dose of 100 mg/kg, the gastric secretion was almost completely inhibited. 25 Curative effect of crude PS in dose of 25 mg/kg (p.o.) on acetic acid-induced ulceration was also observed. We postulate that a reduction in the gastric secretion by PS would cause a reduction in gastric digestion ability to generate food intake restriction. The discrete parameters of each measurement were counted, averaged and statistically analyzed. b The percentages of LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) over total cholesterol (TC) in each specimen were counted, averaged and statistically analyzed. Platycodin saponins reduce the obesity via lipase inhibition and calorie restriction HL Zhao et al PS was also reported to possess an inhibitory effect to the central nervous system (CNS). 25 In folk medicine, it was used as a sedative and pain pacifier. The link between anorexia and a depressed CNS stimulation may exist, but this viewpoint needs further study. In our treatment group, the hepatic TG, TC, and the adipose fat pads covering the liver surface was diminished ( Table 5 ). The serum ALT and AST levels were not changed. On histological examination, no noticeable change was observed in the liver and kidney biopsy. It suggests that PS has some hepatic protective effect as well.
The concentrations of serum TG, TC, and LDL-C were decreased significantly while the levels of HDL-C were almost unchanged. It suggests that the cholesterol-lowering effect of PS was due to the reduction of LDL-C exclusively (Table 4) .
In a series of in vitro assays, PS was also discovered to inhibit the hACAT (acyl-coenzyme A: cholesterol acyltransferase) activity and antagonize the FXR (farnesoid X receptor) binding, implicating a deep involvement in cholesterol metabolism via both repressing the cholesterol ester formation and accelerating the transfer of cholesterol into bile acids (in preparation).
In summary, the inhibitory effect of PS on pancreatic lipase was mainly due to the characteristic structure of PRS moiety in PS. Beyond lipase inhibition, other pathways mediating the effect were also involved. Two essential factors are noted here: one is the suppression of the food intake with high correlation to the body weight loss; the other is the regulation of the cholesterol metabolism with the resultant improvement of the lipoprotein composition and the hepatic lipid-lowering effect. Undoubtedly, PS is more deeply involved in lipid metabolism regulation than was previously understood, 2 and represents a promising candidate in the treatment of the obesity and hyperlipidemia.
